Recent advancements have allowed the development of targeted therapeutics for specific KRAS mutations – for example, Sotorasib and the potential Adagrasib for KRAS G12C mutation, currently with applicability in non-small cell lung cancer harboring KRAS G12C mutation [29]. Here, KRAS is linked to non-small cell lung carcinoma.